Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...
Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...
Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open-label ...
Welcome to Medicare Part D, where your prescription drugs come with co-pays and co-insurance. If you thought co-pays and ...
The study confirmed that TAH3311 is bioequivalent to U.S. and European reference Apixaban tablets (Eliquis®) under fasting conditions, with Cmax and AUC values falling within the regulatory ...
TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent ...
Among those assigned to a DOAC, 53.8% used apixaban (Eliquis, Bristol Myers Squibb/Pfizer), 20.9% used dabigatran (Pradaxa, Boehringer Ingelheim), 18.4% used edoxaban (Savaysa, Daiichi Sankyo ...